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Abstract
Background: Patients with advanced coronary artery disease (CAD) have an unfavorable
prognosis. Therefore, early identification of this high-risk group is important. The aim of this
study was to assess the usefulness of clinical, electrocardiographic and echocardiographic
parameters supported by novel atherogenesis and angiogenesis markers in identifying patients
with stable, three-vessel coronary artery disease.
Methods: The study group comprised 107 patients suffering from three-vessel CAD and
a control group of 15 patients presenting with typical angina, a positive exercise stress test and
abnormal segmental contractility, but no hemodynamically significant coronary stenosis in
their angiograms. In each patient, we characterized a biochemistry test panel including novel
markers: angiogenin, resistin, adiponectin, IL-8 and a TNF-a. The angiographic severity of
CAD was expressed as a Gensini score.
Results: There were significant differences between three-vessel CAD patients and control
groups with respect to the serum levels of: hsCRP (2.8 vs 1.4 mg/L, p = 0.01), HDL-cholesterol
(45 vs 54 mg/dL, p = 0.04), LDL-cholesterol (102 vs 95 mg/dL, p = 0.04), NT-proBNP (392
vs 151 pg/mL, p = 0.008) and a marker of angiogenetic activity, angiogenin (414 vs 275 ng/mL,
p = 0.02), However, no significant differences were found between three-vessel CAD and the
control group with respect to the serum level of adiponectin (8.08 vs 7.82 µg/mL), resistin
(17.5 vs 21 ng/mL), IL-8 (20.7 vs 26.8 pg/mL) and TNF-a (4.1 vs 4.3 pg/mL). Angiogenin
tended to be higher in patients with higher Gensini scores (p = 0.06) but no influence of
ejection fraction was noted.
Conclusions: Angiogenin is a novel marker of three-vessel coronary disease showing a rela-
tionship with the angiographic severity of the disease. (Cardiol J 2010; 17, 6: 599–606)
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Introduction
Coronary artery disease (CAD) is the main
cause of death in developed countries [1]. Despite
recent progress in cardiology, global cardiovascu-
lar mortality is still very high, exceeding seven
million in 2002 [2]. Multivessel coronary artery dis-
ease (MCAD), defined as subcritical or critical
stenosis (cross-section area decreased by ≥ 75%)
of at least two of the three main coronary arteries
supplying the myocardium, is a common manifes-
tation of advanced coronary atherosclerosis [2].
According to various sources, it has been estimat-
ed that it accounts for up to 50% of all cases of CAD.
The severity of atherosclerosis and numerous com-
plications, with a concomitant lack of clear classifi-
cation systems and diagnostic criteria, bring about
an exceptionally high mortality rate in this popula-
tion, which in five-year follow-ups ranges from 10%
to as much as 60%, depending on the advancement
of atherosclerotic lesions and other risk factors [3].
Considering the widespread unfavorable clini-
cal course and poor prognosis of the discussed dis-
ease, based on interpretation of some diagnostic
tests it would be very useful for clinicians to be able
to initially group patients into those at high risk of
severe CAD. A central aim of current cardiological
research is finding markers which would allow for
early diagnosis of MCAD with high specificity. Fac-
tors affecting this quest include adipocytokines and
angiogenesis.
Adipose tissue is now recognized as an endocrine
organ. Adiponectin, an adipocytokine, is a recently
discovered protein that seems to play an anti-in-
flammatory role and regulates inflammatory re-
sponses in atherosclerotic lesions [4]. Hypoadi-
ponectinemia has been observed in patients with
metabolic syndrome, diabetes mellitus and coronary
artery disease [5–7]. Published data supports
a strong association between plasma adiponectin
levels and atherosclerotic burden [8]. That is why
hypoadiponectinemia is considered an independent
risk factor and some recent studies have shown that
plasma adiponectin levels in patients with MCAD
were significantly lower than those in patients with
single vessel coronary artery disease [9].
Resistin belongs to a novel family of cysteine-
-rich proteins called resistin-like molecule or found
in inflammatory zones proteins [10]. Resistin ap-
pears to be involved in inflammatory pathways, ac-
tivating vascular endothelial cells, and stimula-
ting smooth muscle cell proliferation; which sug-
gests a potential role in atherosclerosis [11, 12].
Recently, resistin mRNA and protein have been
reported to be present in atherosclerotic lesions
[13]. This is supported by the fact that levels of cir-
culating resistin increase in patients who have CAD,
and it is an inflammatory marker of atherosclerosis
in humans.
Angiogenin is a soluble protein belonging to
angiogenic factors which are committed in the cre-
ation of capillaries, which leads to the formation of
new vessels from pre-existing vascular structures
[14]. Several studies have suggested that angioge-
nin, and other angiogenic factors, could promote
atherosclerosis and potentially destabilize coronary
plaques by promoting intralesional angiogenesis
[15, 16]. Moreover, angiogenin has been shown to
be an independent predictor of prognosis in coro-
nary heart disease [17].
The aim of this study was to determine the cli-
nical characteristics extended by the determination
of novel atherogenesis markers, as well as angio-




The study involved a group of 107 patients
hospitalized at the 2nd Department of Cardiology,
Medical University in Lodz in 2007 who met the
following criteria: (1) Coronary artery disease with
≥ 75% diameter stenosis in three main coronary
branches (right coronary artery, circumflex branch
and left anterior descending branch of left coronary
artery) as confirmed on coronary angiography.
Stenosis of the left main coronary artery exceed-
ing 50% represented an exlusion criterion due to
the need for urgent revascularization; (2) Stable co-
ronary heart disease (CCS I–III); (3) Absence of sig-
nificant acquired valve disease resulting in predict-
ed survival below one year.
The control group consisted of 15 patients with
a history of typical, exercise-induced stenocardial
symptoms, a clinically or electrographically positive
exercise stress test, segmental contractility distur-
bances on echocardiography, with CAD confirmed
on angiography but with non-significant coronary
artery lumen narrowings (< 50%).
Following discharge from the Department, all
patients remained under the care of the Cardiology
Outpatient Clinic and were treated according to the
guidelines of the European Society of Cardiology.
Patients included in the study signed an informed
consent form to participate; the study was also ap-
proved by the Bioethics Committee at the Medical
University in Lodz (Poland).
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Biochemical tests
All patients had additional tests performed in
order to evaluate disease severity and possible dys-
functions of other organs: complete blood count,
complete lipid profile, fasting blood glucose (and in
non-diabetic patients an oral glucose tolerance test
with blood glucose measurement after two hours),
CK-MB, urea, creatinine, hepatic transferases,
C-reactive protein and NT-proBNP levels. Apart
from standard biochemical parameters, we exami-
ned novel markers such as adiponectin, resistin,
TNF-a, interleukin-8 (IL-8) and angiogenin, which
are useful in the assessment of the severity of
pathophysiological processes promoting athero-
genesis.
Methodology of cytokine measurement
To assess the serum level of novel atheroscle-
rosis markers, the ELISA method applying ready
tests manufactured by the Biocom (angiogenin) and
Biker (adiponectin, resistin, TNF-a and IL-8) com-
panies was performed.
Electrocardiography, echocardiography,
exercise stress test and
coronary angiography
Transthoracic echocardiography, resting elec-
trocardiography, and electrocardiographic exercise
test were performed at baseline in all patients. Based
on coronary angiographic results, the severity of athe-
rosclerotic changes was semiquantified with the
Gensini score. Lesions formed (involving lesion se-
verity and location) in left main and proximal seg-
ments of left descending artery, circumflex and right
coronary artery were grouped to calculate the proxi-
mal Gensini score, and distal lesions located in the
remaining coronary segments yielded the distal
Gensini score.
Statistical analysis
The Shapiro-Wilk test was used for determin-
ing the normality of distribution of the analyzed
variables. Continuous variables showing normal
distribution are presented as means ± standard
deviations, whereas constant variables of distribu-
tion different from normal and ordinal variables are
expressed as medians (25th–75th percentile). Va-
riance analysis and the Wilcoxon non-parametric
test were applied to compare the differences in the
presence of particular features in patient groups.
The relationship between continuous variables of
normal distribution was analyzed using linear Pear-
son’s correlation analysis. If at least one variable
showed other than normal distribution, or was of
ordinal type, Spearman rank correlation analysis
was applied. The results were considered statisti-
cally significant if the p value was < 0.05.
Results
Patients with three-vessel coronary artery dis-
ease (TVCAD) had a long history of angina (mean
52 months) and most of them (73%) had previous
myocardial infarction. In the study group, the de-
tection of obliterative atherosclerosis of the lower
limbs, atrial fibrillation, a positive medical history,
stroke and smoking were more common. The dis-
tribution of other CAD risk factors in the study
group revealed no significant differences in compar-
ison to the control group. Detailed data is shown in
Table 1. All patients with TVCAD had ischemic
changes on electrocardiography. In most cases,
pathological Q waves, negative T waves and ST
depression were observed. In patients with
TVCAD, echocardiography showed much more ag-
gravated segmental contractility disorders, and left
ventricular ejection fraction was significantly low-
er than in controls (Table 2). Exercise test was
more often electrographically positive in TVCAD
patients (p = 0.01; Table 3). The mean Gensini
score in TVCAD patients was 91 (66–132), with
the proximal Gensini score being 45 (20–90) and the
distal one 39 (20–70). There were significant dif-
ferences between TVCAD patients and control
groups with respect to serum levels of: hsCRP
(2.8 vs 1.4 mg/L, p = 0.01), HDL-cholesterol (45 vs
54 mg/dL, p = 0.04), LDL-cholesterol (102 vs 95 mg/
/dL, p = 0.04), NT-proBNP (392 vs 151 pg/mL,
p = 0.008) and angiogenin (414 vs 275 ng/mL, p = 0.02),
However, no significant differences were found
between the TVCAD and control groups with re-
spect to the serum level of adiponectin (8.08 vs
7.82 µg/mL), resistin (17.5 vs 21 ng/mL), IL-8 (20.7
vs 26.8 pg/mL) and TNF-a (4.1 vs 4.3 pg/mL; Table 4).
In addition, a negative correlation between
adiponectin and both triglyceride (r = –0.2, p = 0.02)
and serum IL-8 levels (r = –0.2, p = 0.03) and
a positive correlation between adiponectin and
NYHA class (r = 0.3, p = 0.0025), NT-proBNP
(r = 0.4, p < 0.0001) and LDL serum levels (r = 0.4,
p = 0.0001) was documented in TVCAD patients.
There was a positive correlation between angioge-
nin and NT-proBNP (r = 0.3, p = 0.001), resistin
(r = 0.3, p = 0.001) and TNF-a serum levels
(r = 0.3, p = 0.005) as well as resistin levels and
NYHA class (r = 0.2, p = 0.02) levels (Table 5).
Serum adiponectin concentration was significantly
lower in males (7.38 vs 12.6 µg/mL, p = 0.015).
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Moreover, angiogenin tended to be higher in pa-
tients with higher Gensini scores (357 ng/mL in the
group with a Gensini score of < 90 and 417 ng/mL
in the group with a Gensini score of > 90; p = 0.06)
but no influence of the ejection fraction was noted
(374 ng/mL in the group with ejection fraction
< 40% and 421 ng/mL in the group with ejection
fraction > 40%, p = 0.1).
Discussion
An initial selection of patients with a high risk
of multivessel CAD, made on the basis of interpre-
tation of some biochemical and imaging tests, would
allow for a much earlier qualification for invasive
procedures, thus limiting the frequency of cardio-
vascular adverse events in this group. Medical his-
Table 2. Summary of echocardiography and resting electrocardiogram results in patients with
three-vessel coronary artery disease (TVCAD) and in control groups.
TVCAD group (n = 107) Control group (n = 15) p
Ejection fraction (%) 45 ± 11 55 ± 6 0.005
Left atrium diameter [mm] 42 ± 5 40 ± 4 NS
Aorta diameter [mm] 34 ± 4 33 ± 4 NS
LVDD [mm] 49 (48–55) 46 (44–47) 0.007
LVSD [mm] 35 (30–42) 30 (27–36) 0.004
Heart rate [hbm] 69 (62–79) 68 (62–85) NS
ST elevation > 1 mm 10 (9%) 0 (0%) 0.001
ST depression >1 mm 30 (28%) 4 (27%) NS
Negative T waves 63 (59%) 9 (60%) NS
Pathological Q wave 62 (58%) 0 (0%) < 0.001
LBBB 3 (3%) 1 (7%) NS
Left anterior hemiblock 7 (7%) 2 (13%) NS
RBBB 4 (4%) 1 (7%) NS
Non corrected QT [ms] 388 ± 38 363 ± 33 NS
LVDD — Left ventricular diastolic diameter; LVSD — left ventricular systolic diameter; LBBB — left bundle branch block; RBBB — right bundle branch
block
Table 1. Selected demographic data of patients with three-vessel coronary artery disease (TVCAD)
and control groups.
TVCAD group (n = 107) Control group (n = 15) p
Males 79 (74%) 8 (53%) 0.04
Age 63.1 ± 8.5 59.7 ± 10.8 NS
Duration of angina (months) 52 (20–98) 6 (1–10) 0.001
History of myocardial infarction 73 (68%) 0 (0%) < 0.001
NYHA class 2 (1–2.5) 0 (0–0) < 0.001
CCS class 2.5 (2–3) 1 (0–2) 0.01
Kidney failure 3 (3%) 1 (7%) NS
Hypertension 104 (97%) 13 (87%) NS
Diabetes mellitus 51 (48%) 6 (40%) NS
Impaired glucose tolerance 34 (32%) 4 (27%) NS
Obesity 37 (35%) 5 (33%) NS
Body mass index 28.8 ± 3.9 28.8 ± 3.3 NS
Smoking 34 (32%) 2 (13%) 0.01
Positive family history 28 (26%) 1 (7%) 0.01
Atrial fibrillation 5 (5%) 0 0.05
Atherosclerosis of peripheral arteries 18 (17%) 0 0.002
Stroke 5 (5%) 0 0.05
NYHA — New York Heart Association; CCS — Canadian Cardiovascular Society
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tory, together with the interpretation of some se-
lected routine imaging studies, appears to be the
key aspect of management in this case. In light of
the above, novel biochemical markers, such as the
marker of angiogenetic activity (angiogenin), have
shown promising results. However, we did not find
that knowledge of the serum levels of selected adi-
pocytokines (adiponectin and resistin), as well as
novel inflammatory markers (IL-8 and TNF-a) made
it possible to obtain additional information on the
discussed aspect. Importantly, in this study we con-
firm many of the metabolic associations reported
previously for resistin and adiponectin [11, 18, 19].
Specifically, in our study, lower levels of adiponec-
tin were seen in association with hypertriglyceri-
demia and high HDL-cholesterol concentrations.
We also report a strong positive correlation be-
tween adiponectin and resistin levels and heart
failure symptoms as well as NT-proBNP serum
concentration. In this regard, our findings are in
accord with the literature and support the validity
of our dataset.
Table 4. Selected laboratory test results in the three-vessel coronary artery disease (TVCAD) group
and the control group
TVCAD group (n = 107) Control group (n = 15) p
Adiponectin [µg/mL] 8.08 (5.8–12.9) 7.82 (4.6–8.9) NS
Resistin [ng/mL] 17.5 (12.5–25.4) 21 (16.6–24.3) NS
Interelukin-8 [pg/mL] 20.7 (12–30) 26.8 (12.6–40.1) NS
TNF-a [pg/mL] 4.1 (2.3–4.9) 4.3 (4–4.4) NS
Angiogenin [ng/mL] 414 (326–521) 275 (127–447) 0.02
Hemoglobin [g/dL] 14.5 ± 1.3 14.6 ± 1.5 NS
WBC [×103/µL] 7.5 (6.4–9.6) 7.4 (6.6–7.9) NS
PLT [×103/µL] 251 ± 67 239 ± 48 NS
Total cholesterol [mg/dL] 171 (148–210) 185 (169–199) NS
HDL [mg/dL] 45 (39–52) 54 (43–63) 0.04
LDL [mg/dL] 102 (79–128) 96 (84–116) 0.04
Triglycerides [mg/dL] 131 (94–184) 150 (115–202) NS
hsCRP [mg/L] 2.8 (1.6–5.4) 1.4 (1.1–2) 0.01
Urea [mg/dL] 34 (29–42) 28 (24–39) 0.025
Creatinine [mg/dL] 0.91 ± 0.13 0.89 ± 0.18 NS
Uric acid [mg/dL] 6 ± 1.2 5.3 ± 1.3 NS
GFR [mL/min/1.73 m2] 92 (79–118) 113 (70–122) NS
NT-proBNP [pg/mL] 392 (162–850) 151 (83–221) 0.008
HbA1c (%) 6 (5.6–7.1) 5.8 (5.7–6.2) NS
Fibrinogen [mg/dL] 385 (335–440) 360 (315–455) NS
WBC — white blood count; PLT — platelets; hsCRP — high sensitivity C-reactive protein; GFR — glomerular filtration rate; HbA1c — hemoglobin A1c
Table 3. Characteristics of the three-vessel coronary artery disease (TVCAD) group
and the control group regarding exercise test results.
TVCAD group (n = 90) Control group (n = 15) p
Workload [METS] 5.5 (4–7) 6 (4.8–8) NS
Significant ST depression 67 (74%) 7 (47%) 0.02
Significant ST elevation 4 (4%) 0 (0%) NS
Left bundle branch block 3 (3%) 0 (0%) NS
Electrographically positive test 74 (83%)  7 (47%) 0.01
Non diagnostic test 11 (12%) 6 (40%) 0.03
Electrographically negative test 5 (5%) 2 (13%) NS
METS — metabolic equivalents
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Understanding mechanisms underlying the
atherosclerotic process, from a pathologist’s point
of view being a form of inflammatory response to
factors damaging the vessel wall, has made it pos-
sible to identify many markers of inflammatory re-
sponse crucial in atherogenesis. A new, recently
revealed inflammatory marker, closely connected
to atherosclerosis, is the fat cell protein product,
resistin. There are many studies showing elevated
serum resistin levels in CAD patients which indi-
cate the severity of the inflammatory response con-
nected with atherogenesis [20]. The reports pub-
lished so far on the relationship between resistin
levels and progression, severity and prognosis of
patients with CAD give contradictory information.
Reilly et al. [20] demonstrated a relationship be-
tween resistin levels and the degree of coronary
artery calcification (‘calcium score’) computed on
the basis of the interpretation of imaging from com-
puted tomography performed in asymptomatic pa-
tients. In addition, based on angiographic evaluation,
Ohmori et al. [11] came to the conclusion that there
is a correlation between the resistin level and the
number of stenoses in coronary arteries. Hu et al. [21]
also documented significantly different concentra-
tions of resistin in stable and unstable CAD, thus
confirming the role of resistin in risk stratification
of atherosclerotic plaque destabilization in CAD
patients. On the other hand, Pilz et al. [22] did not
show any correlation between resistin levels and
the severity of atherosclerosis in a group of 1,100
patients, though a high level of resistin was a strong
and independent predictor of non-fatal cardiovascu-
lar events in this group. Similar conclusions follow
from research conducted by Hoefle et al. [23], where
in a group of 547 patients, there were no significant
differences in serum resistin between patients with
CAD and those in whom angiography did not show
CAD, nor between patients with ≥ 50% coronary
narrowings and those without such lesions.
Another substance recently detected and found
to be useful in the risk stratification of multivessel
CAD is adiponectin, the insulin-sensitizing, anti-
inflammatory anti-atherosclerotic protein. The
pleiotrophy of adipokine activity is the reason for
performing a number of clinical studies investiga-
ting its usefulness in everyday medical practice. Our
findings with respect to the lack of correlation be-
tween adiponectin levels and the severity of athero-
sclerosis in coronary vessels are in contrast to many
other studies that have reaffirmed a strong relation-
ship between a low serum level of adiponectin and
the severity of CAD. According to Otsuka et al. [9],
in a group of 207 patients with confirmed CAD,
a level of adiponectin lower than 4 mg/mL is a strong
and independent predictor of severe atherosclero-
sis of coronary arteries (OR 2.14, p = 0.027). Miłosz
et al. [24] drew similar conclusions: mainly that
hypoadiponectinemia and exacerbation of inflamma-
tory processes, expressed by C-reactive protein and
sVCAM-1 concentrations, were responsible for
a greater escalation of atherosclerosis in coronary
arteries. These conflicting observations may relate,
at least in part, to the markedly different risk pro-
Table 5. Correlations between selected parameters in the study group.
Adiponectin Resistin Interleukin-8 TNF-a Angiogenin
NYHA class r = 0.3 r = 0.2 r = –0.15 r = –0.03 r = –0.04
p = 0.0025 p = 0.02 p = NS p = NS p = NS
NT-proBNP r = 0.4 r = 0.04 r = –0.04 r = 0.2 r = 0.3
p < 0.0001 p = NS p = NS p = NS p = 0.001
HDL-cholesterol r = 0.4 r = 0.05 r = –0.07 r = 0.04 r = –0.04
p = 0.0001 p = NS p = NS p = NS p = NS
Triglycerides r = –0.2 r = –0.04 r = –0.05 r = 0.04 r = 0.06
p = 0.02 p = NS p = NS p = NS p = NS
Adiponectin r = –0.1 r = –0.2 r = 0.03 r = –0.04
p = NS p = 0.03 p = NS p = NS
Resistin r = –0.1627 r = 0.1 r = 0.2 r = 0.3
p = NS p = NS p = NS p = 0.001
Interleukin-8 r = –0.2 r = 0.1 r = 0.1 r = 0.1
p = 0.03 p = NS p = NS p = NS
TNF-a r = 0.03 r = 0.16 r = 0.1 r = 0.3
p = NS p = NS p = NS p = 0.005
Angiogenin r = –0.04 r = 0.3 r = 0.1 r = 0.3
p = NS p = 0.001 p = NS p = 0.005
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files of the populations in our study. Our study po-
pulation consisted of a relatively high-risk cohort as
manifested not only in the clinical, angiographic, and
laboratory data, but also in the high incidence of
heart failure. Indeed, it is well-established that pa-
tients with heart failure symptoms have higher base-
line levels of adiponectin, which may be a consequence
of resistance at the level of the adiponectin receptor,
a mechanism potentially akin to that seen in diabetics
with elevated insulin levels [25, 26].
The presence of coronary collateralization im-
proves the prognosis of patients with advanced
CAD. Collaterals improve ventricular function and
overall perfusion in the ischemic myocardium [27].
The development of coronary collaterals appears to
be initiated by ischemia resulting in the opening of
pre-existing anastomotic channels through an in-
crease in shear forces and pressure, or by forma-
tion of new capillary sprouts (angiogenesis). On the
other hand, there is strong evidence that the de-
velopment of human atherosclerotic plaques is as-
sociated with the formation of new microvessels
within the plaque [16, 28]. That is why the role of
angiogenesis remains highly contentious, and no
consensus exists as to whether angiogenesis is the
key causative factor in the pathogenesis of athero-
sclerotic plaque formation, or a way to treat CAD.
Our data demonstrates that the serum level of an-
giogenin is about 35% higher in patients with mul-
tivessel coronary heart disease than in patients
without significant narrowings in the coronary ar-
teries. These findings are consistent with data com-
ing from Tello-Montoliu et al. [17], where the authors
demonstrated in a group of 516 patients that ‘acute
coronary syndrome’ patients had significantly eleva-
ted plasma angiogenin levels as compared with both
diseased controls (stable CAD) and healthy controls
(p < 0.001). However, the authors did not find any
correlation between angiogenin and the severity of
atherosclerosis expressed as a Gensini score; raised
angiogenin levels were independently associated
with more adverse events at a six month follow-up.
Other pro-angiogenic molecules have been studied
in coronary heart disease, in particular VEGF, hepa-
tocyte growth factor, and angiopoietin types 1 and 2.
In all the studies, patients presenting with advanced
atherosclerosis had significantly higher levels of
pro-angiogenic effector molecules as compared to
(usually healthy) controls [29–31].
Limitations of the study
This study is limited by the relatively small
control group and the high variety of risk profiles
in the study group. Finding a more homogenous
group of patients (especially as regards heart fail-
ure symptoms) might help to better understand the
chain of complex relationships between inflamma-
tion, atherosclerosis and angiogenesis.
Conclusions
The ability of each clinician to perform risk
stratification of atherosclerosis severity in coronary
arteries is very important. Angiogenin is a novel
marker of three-vessel coronary disease, showing
a relationship with the angiographic severity of the
disease. This initial demonstration of the diagnos-
tic potential of the marker warrants further studies
on its practical usefulness and relationship to es-
tablished clinical factors.
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